Kymera Therapeutics, Inc.
KYMR
$117.39
$2.972.60%
NASDAQ
| 06/30/2026 | 03/31/2026 | 12/31/2025 | 09/30/2025 | 06/30/2025 | |
|---|---|---|---|---|---|
| Net Income | -299.60M | -315.00M | -311.35M | -295.12M | -275.43M |
| Total Depreciation and Amortization | 8.23M | 8.29M | 8.31M | 8.27M | 8.11M |
| Total Amortization of Deferred Charges | -- | -- | -- | -- | -- |
| Total Other Non-Cash Items | 59.77M | 56.45M | 54.88M | 53.00M | 46.82M |
| Change in Net Operating Assets | -5.16M | 7.69M | 15.27M | 5.92M | -30.50M |
| Cash from Operations | -236.76M | -242.58M | -232.89M | -227.93M | -251.01M |
| Capital Expenditure | -1.19M | -1.42M | -1.45M | -2.28M | -1.91M |
| Sale of Property, Plant, and Equipment | -- | -- | -- | -- | -- |
| Cash Acquisitions | -- | -- | -- | -- | -- |
| Divestitures | -- | -- | -- | -- | -- |
| Other Investing Activities | -751.30M | -711.10M | -519.61M | -55.82M | 21.43M |
| Cash from Investing | -752.49M | -712.52M | -521.06M | -58.10M | 19.52M |
| Total Debt Issued | -- | -- | -- | -- | -- |
| Total Debt Repaid | -1.70M | -1.64M | -1.49M | -1.37M | -1.59M |
| Issuance of Common Stock | 831.51M | 1.06B | 1.04B | 317.99M | 529.62M |
| Repurchase of Common Stock | -- | -- | -- | -- | -- |
| Issuance of Preferred Stock | -- | -- | -- | -- | -- |
| Repurchase of Preferred Stock | -- | -- | -- | -- | -- |
| Total Dividends Paid | -- | -- | -- | -- | -- |
| Other Financing Activities | -51.90M | -51.90M | -51.90M | -28.36M | -28.36M |
| Cash from Financing | 777.92M | 1.01B | 990.71M | 288.26M | 499.67M |
| Foreign Exchange rate Adjustments | -- | -- | -- | -- | -- |
| Miscellaneous Cash Flow Adjustments | -- | -- | -- | -- | -- |
| Net Change in Cash | -211.34M | 54.13M | 236.76M | 2.24M | 268.18M |